Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma (CLASSE)

The main objectives of this study are to show that the number of type 2 innate lymphoid cells (ILC2) of the bronchial mucosa and in bronchoalveolar lavages (BAL) are higher in asthmatic children than in non-asthmatics, that the number of ILC2 of the bronchial mucosa and in BAL correlate with the number of bronchial and BAL eosinophils, and to determine whether there is a correlation between plasma and bronchial and BAL ILC2.

Study Overview

• Status: Withdrawn
• Conditions: Severe Asthma
• Intervention / Treatment: Biological: Biopsy; Biological: Blood collection; Biological: Bronchoalveolar lavage

Detailed Description

Severe asthma of the child is characterized by chronic eosinophilic infiltration of the bronchial mucosa associated with bronchial remodeling.

The mechanisms responsible for these phenomena are still misunderstood. Animal models suggest that type 2 innate lymphoid cells (ILC2) may be responsible for inflammation and bronchial remodeling in asthma. In mice, ILC2 stimulated by the pulmonary epithelium by viral aggression or allergenic exposure release cytokines of the TH2 type such as IL-5 and IL-13 and amphiregulin, involved in the recruitment and differentiation of eosinophils, bronchoconstriction, mucus secretion and the restoration of epithelial integrity.

In humans, ILC2 would be more abundant in the bronchoalveolar lavage (BAL) and peripheral blood of asthmatic patients compared to control subjects. However, the presence of ILC2 in the bronchial mucosa of asthmatic patients has never been identified.

The hypothesis tested is that ILC2 are more abundant in bronchial mucosa, BAL, and blood in children with severe asthma than in non-asthmatics. The results of this study would improve the knowledge of the mechanisms responsible for bronchial inflammation in asthma, consider therapies to prevent its development and modify the natural history of the disease.

The main objectives of this study are to show that the number of ILC2 in bronchial mucosa and BAL is higher in asthmatic children than in non-asthmatics, that the number of ILC2 in the bronchial mucosa and BAL is correlated with the number of eosinophils in bronchial mucosa and BAL, to determine whether the number of ILC2 in lungs correlate with asthma symptoms, and to determine whether there is a correlation between plasma and bronchial ILC2.

Bronchoscopy with BAL and bronchial mucosal biopsies will be performed in 20 children with severe asthma and 20 control subjects in the department of pediatric pulmonology and allergy of Necker Hospital.

ILC2 will be identified in the BAL, in the bronchial mucosa and peripheral blood by flow cytometry. The median values of the number of ILC2 will be compared between asthmatic and non-asthmatic patients by the Mann-Whitney non-parametric test. The correlations will be established by the Spearman rank test. A value of p < 0.05 will be considered significant.

• Study Type: Observational

Contacts and Locations

Study Locations

• France
  • Paris, France, 75015
    • Hôpital Necker Enfants Malades

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 18 years (ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Minors hospitalized in the department of pediatric pulmonology and allergy of Necker Hospital

Description

Inclusion Criteria:

Controls :

• Minors aged 6 to 18 matched in age with severe asthmatic children
• Non-asthmatic children hospitalized in the department of pediatric pulmonology and allergy in Necker Hospital
• To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood collection

Severe asthmatic children :

• Minors aged 6 to 18
• Children hospitalized in the department of pediatric pulmonology and allergy in Necker Hospital
• To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood collection
• Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene

Exclusion Criteria:

• Children with an immune deficiency, will be excluded

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Asthmatic children; Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene	Biological: Biopsy; Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe; Biological: Blood collection; Blood collection (+15mL/ current care); Biological: Bronchoalveolar lavage; Bronchoalveolar lavage fluid (3mL/Kg)
Controls; Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.	Biological: Biopsy; Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe; Biological: Blood collection; Blood collection (+15mL/ current care); Biological: Bronchoalveolar lavage; Bronchoalveolar lavage fluid (3mL/Kg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of type 2 innate lymphoid cells	Type 2 innate lymphoid cells	Day 0

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Eosinophils	Eosinophils	Day 0
Airway remodeling: reticular basement membrane thickness	Reticular basement membrane thickness will be expressed in µm.	Day 0
Airway remodeling: airway smooth muscle area	The percentage of the submucosa occupied by airway smooth muscle will be determined on hematoxylin-eosin-stained and anti-airway smooth muscle antibody treated sections, respectively. The bundles of airway smooth muscle will be enclosed by a line and the area they occupied will be calculated by image analysis. The airway smooth muscle area will be expressed as the percentage of surface of the submucosa occupied by airway smooth muscle.	Day 0
Airway remodeling: epithelial integrity	Epithelial integrity will be defined as the percentage of the total length of epithelium that will be intact.	Day 0
Airway remodeling: vessel number	The number of vessels stained with anti-CD31 mAb will be determined from at least one grid (0.1 mm2) per biopsy, and reported as the median number of positive sections per 0.1 mm2.	Day 0
Airway remodeling: mucus gland area	The percentage of the submucosa occupied by mucus gland will be determined on hematoxylin-eosin-stained and anti-airway smooth muscle antibody treated sections, respectively. The mucus glands will be enclosed by a line and the area occupied will be calculated by image analysis. The mucus gland area will be expressed as the percentage of surface of the submucosa occupied by mucus gland.	Day 0
Airway inflammation: bronchoalveolar lavage (BAL)	BAL fluid will be assed for inflammation; The number of eosinophils will be assessed and expressed percentage of total cells in BAL; The number of neutrophils will be assessed and expressed percentage of total cells in BAL; The number of macrophages will be assessed and expressed percentage of total cells in BAL; The number of basophils will be assessed and expressed percentage of total cells in BAL; The number of mast cells will be assessed and expressed percentage of total cells in BAL; The number of innate lymphoid cells will be assessed and expressed percentage of total cells in BAL; The number of mucosal associated invariant T (MAIT) cells will be assessed and expressed percentage of total cells in BAL; The number of invariant natural killer T cells will be assessed and expressed percentage of total cells in BAL; The number of gammadelta T cells will be assessed and expressed percentage of total cells in BAL	Day 0
Airway inflammation: bronchial mucosa	Bronchial sections will be stained with May-Grunwald-Giemsa.The number of inflammatory cells will be assessed in the submucosa and expressed as the number of cells per square millimeters of submucosal area.; The number of eosinophils will be assessed and expressed per square millimeters of submucosal area; The number of neutrophils in the submucosa will be assessed and expressed per square millimeters of submucosal area; The number of mast cells (c-kit positive cells) in the submucosa will be assessed and expressed per square millimeters of submucosal area; The number of IgE stained with anti-IgE Ab in the submucosa and the epithelium will be assessed and expressed per square millimeters of submucosal area; The expression of cytokines in the mucosa will be assessed by multiplex	Day 0
Inflammation in blood	The number of eosinophils will be assessed and expressed percentage of total cells in blood; The number of neutrophils will be assessed and expressed percentage of total cells in blood; The number of basophils will be assessed and expressed percentage of total cells in blood; The number of lymphocytes will be assessed and expressed percentage of total cells in blood; The number of innate lymphoid cells will be assessed and expressed percentage of total cells in blood; The number of mucosal associated invariant T (MAIT) cells will be assessed and expressed percentage of total cells and T cells in blood; The number of invariant natural killer T cells will be assessed and expressed percentage of total cells and T cells in blood; The number of gammadelta T cells will be assessed and expressed percentage of total cells and T cells in blood; The expression of cytokine will be assessed using multiplex analysis	Day 0
Metabolomic signature	Non-targeted metabolomics analysis will be performed on plasma. Metabolic profiles will be obtained using two complementary LC-MS methods, to identify metabolites discriminating different patients.	Day 0
Microbiota analysis	Microbiota analysis will be performed on BAL using PCR ARN 16S.	Day 0

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 9, 2016
• Primary Completion (ANTICIPATED): April 1, 2020
• Study Completion (ANTICIPATED): April 1, 2020

Study Registration Dates

• First Submitted: November 2, 2018
• First Submitted That Met QC Criteria: December 20, 2018
• First Posted (ACTUAL): December 24, 2018

Study Record Updates

• Last Update Posted (ACTUAL): November 8, 2022
• Last Update Submitted That Met QC Criteria: November 7, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: Severe asthma in children; Type 2 innate lymphoid cells (ILC2); bronchial mucosa; bronchoalveolar lavages
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Dimercaprol
• Other Study ID Numbers: APHP180357

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No